← Back to Clinical Trials
Recruiting NCT07023185

NCT07023185 Cold and Compression Post TKA

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07023185
Status Recruiting
Phase
Sponsor Ochsner Health System
Condition Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery
Study Type INTERVENTIONAL
Enrollment 90 participants
Start Date 2025-12-15
Primary Completion 2027-06

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Cold and CompressionSOC (Standard of care)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 90 participants in total. It began in 2025-12-15 with a primary completion date of 2027-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to compare pain score (Patient-Reported Outcomes Measurement Information System: PROMIS NRS Pain Subscale) between the control and cold/compression groups pre-surgically, daily after surgery for 14 days, then weekly after surgery for 3 months, and at 6 months post-surgery.

Eligibility Criteria

Inclusion Criteria: 1. Aged 50 yr or older 2. Patient of Dr. Howard Hirsch or Dr. Vinod Dasa scheduled for total knee arthroplasty (knee replacement) at Ochsner Kenner 3. Will receive outpatient physical therapy at OTW Driftwood for the entire post-op rehabilitation period 4. English speaking 5. Diagnosis of primary osteoarthritis Exclusion Criteria: 1. Chronic opioid use 2. Opioid use within the last 3 months 3. PCS score ≥ 30 4. Diagnosis of inflammatory disease process (i.e., gout, rheumatoid arthritis, systematic lupus erythematosus...) 5. Discharge to skilled nursing 6. Cold intolerance related to diseases, like Raynaud's 7. Significant vascular impairment in the affected region 8. Current clinical signs of inflammatory phlebitis, venous ulcers, or cellulitis 9. Significant risk factors or current clinical signs of embolism (e.g., pulmonary embolus, pulmonary edema, cerebral infarction, atrial fibrillation, endocarditis, myocardial infarction, or atheromatous embolic plaque) 10. A condition in which increased venous or lymphatic return is not desired in the affected extremity (e.g., lymphedema after breast cancer or other local carcinoma and/or carcinoma metastasis in the affected extremity). 11. Uncontrolled hypertension (physician discretion), cardiac failure, extreme low blood pressure, or decompensated cardiac insufficiency. 12. Localized unstable skin condition (e.g., dermatitis, vein ligation, gangrene, or recent skin graft) in the affected region. 13. Had recent toe surgery in the affected region 14. Current clinical signs in the affected region of significant peripheral edema (e.g., deep vein thrombosis, chronic venous insufficiency, acute compartment syndrome, systemic venous hypertension, congestive heart failure, cirrhosis/liver failure, renal failure). 15. An acute, unstable (untreated) fracture in the affected region. 16. Any active local or systemic infection. 17. Obtunded or with diabetes mellitus, multiple sclerosis, poor circulation, spinal cord injuries, and rheumatoid arthritis 18. Areas of skin breakdown or damage (damaged or at-risk skin) producing uneven heat conduction across the skin (e.g., open wound, scar tissue, burn or skin graft). Any open wound must be dressed prior to use of the Polar Care Wave System. 19. Presumptive evidence of congestive heart failure 20. Pre-existing DVT condition 21. Deep acute venal thrombosis (Phlebothrombosis) 22. Episodes of pulmonary embolism 23. Pulmonary edema 24. Acute inflammation of the veins (Thrombophlebitis) 25. Decompensated cardiac insufficiency 26. Arterial dysregulation 27. Erysipelas 28. Carcinoma and carcinoma metastasis in the affected extremity 29. Decompensated hypertonia 30. Acute inflammatory skin diseases or infection 31. Venous or arterial occlusive disease 32. Medical situations where increased venous or lymphatic return is undesirable 33. Poor peripheral circulation 34. Severe arteriosclerosis, or active infection 35. Known hematological dyscrasias that predispose to thrombosis (e.g., paroxysmal cold hemoglobinuria, cryoglobulinemia, sicklecell disease, serum cold agglutinins). 36. Tissues inflamed as a result of recent injury or exacerbation of chronic inflammatory condition. 37. Compromised local circulation or neurologic impairment (including paralysis or localized compromise due to multiple surgical procedures or diabetes) in the affected region. 38. Cognition or communication impairments that prevent them from giving accurate and timely feedback. 39. Cold allergy 40. Cold agglutinin disorders like paroxysmal cold hemoglobinuria 41. Buerger's disease 42. Chilblains 43. Cryoglobulinemia 44. Sickle cell anemia 45. Uncontrolled diabetes (physician discretion) 46. Hypersensitivity to cold 47. History of cold injury 48. Severe cardiovascular disease, anesthetic skin, hypercoagulation disorders, poor circulation, extremities sensitive to pain, extremely low blood pressure that are incapacitated, decreased skin sensitivity, vein ligation or recent skin grafts, or pheochromocytoma.

Contact & Investigator

Central Contact

Vinod Dasa, MD

✉ vdasa@lsuhsc.edu

📞 (504) 412-1705

Frequently Asked Questions

Who can join the NCT07023185 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, studying Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07023185 currently recruiting?

Yes, NCT07023185 is actively recruiting participants. Contact the research team at vdasa@lsuhsc.edu for enrollment information.

Where is the NCT07023185 trial being conducted?

This trial is being conducted at New Orleans, United States.

Who is sponsoring the NCT07023185 clinical trial?

NCT07023185 is sponsored by Ochsner Health System. The trial plans to enroll 90 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology